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Although Epstein-Barr virus (EBV)-associated malignancies are primarily composed of cells with one of the
latent forms of EBV infection, a small subset of tumor cells containing the lytic form of infection is often observed.
Whether the rare lytically infected tumor cells contribute to the growth of the latently infected tumor cells is unclear.
Here we have investigated whether the lytically infected subset of early-passage lymphoblastoid cell lines (LCLs)
could potentially contribute to tumor growth through the production of angiogenesis factors. We demonstrate that
supernatants from early-passage LCLs infected with BZLF1-deleted virus (Z-KO LCLs) are highly impaired in
promoting endothelial cell tube formation in vitro compared to wild-type (WT) LCL supernatants. Furthermore,
expression of the BZLF1 gene product in trans in Z-KO LCLs restored angiogenic capacity. The supernatants of
Z-KO LCLs, as well as supernatants from LCLs derived with a BRLF1-deleted virus (R-KO LCLs), contained much
less vascular endothelial growth factor (VEGF) in comparison to WT LCLs. BZLF1 gene expression in Z-KO LCLs
restored the VEGF level in the supernatant. However, the cellular level of VEGF mRNA was similar in Z-KO, R-KO,
and WT LCLs, suggesting that lytic infection may enhance VEGF translation or secretion. Interestingly, a portion
of the vasculature in LCL tumors in SCID mice was derived from the human LCLs. These results suggest that
lytically infected cells may contribute to the growth of EBV-associated malignancies by enhancing angiogenesis. In
addition, as VEGF is a pleiotropic factor with effects other than angiogenesis, lytically induced VEGF secretion may
potentially contribute to viral pathogenesis.
Epstein-Barr virus (EBV), a ubiquitous human herpes virus,
can exist in either a latent or lytic state with regard to viral gene
expression. In the latent forms of infection, a limited subset of
viral genes is expressed, and the virus is replicated using the
host cell DNA polymerase (53). The EBV proteins known to
be important for cellular transformation are expressed during
the type II and type III forms of latent infection (28, 33, 58, 63).
In lytic infection, widespread viral gene expression occurs, re-
sulting in replication of the virus by viral DNA polymerase,
release of infectious virus, and death of the host cell (53).
Entry into lytic cycle is triggered by expression of the two
immediate-early genes of EBV, BZLF1 and BRLF1. The
BZLF1 and BRLF1 gene products function as transcription
factors with the capacity to activate both viral and cellular
promoters (9, 37, 39, 53).
EBV is associated with numerous malignancies of both
B-cell and epithelial cell origin. EBV-associated malignancies
are primarily infected with one of the latent forms of EBV,
although a small subset of lytically infected cells is commonly
detected in biopsies of EBV-positive malignancies (11, 42, 70).
BZLF1-deleted (Z-KO) and BRLF1-deleted (R-KO) viruses
are unable to replicate lytically but can immortalize primary
B cells in vitro with similar efficiency as the wild-type (WT)
virus (17). However, a potential role for lytically infected cells
in promoting tumor growth in vivo was suggested by our recent
finding that early-passage lymphoblastoid cell lines (LCLs)
derived with either Z-KO or R-KO EBV (Z-KO or R-KO
LCLs, respectively) were impaired for growth in SCID mice in
comparison to LCLs infected with WT EBV (WT LCLs) (26).
Restoration of the capacity of Z-KO LCLs to enter the lytic
cycle (accomplished by introducing a BZLF1 expression vector
in trans) resulted in enhanced growth of Z-KO LCLs in SCID
mice. Furthermore, LCLs derived from the Z-KO and R-KO
viruses expressed significantly less interleukin-6 (IL-6), cellular
IL-10, and viral IL-10 in vitro in comparison to WT LCLs,
suggesting that the in vivo tumorigenesis defect may be due at
least partly to decreased secretion of paracrine B-cell growth
factors.
Angiogenesis, or the formation of new blood vessels, is a
critical event for the efficient growth of both B-cell and epi-
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thelial cell malignancies, as all cells must be located within
100 m of a capillary in order to survive (8). In addition,
angiogenesis provides tumor cells with access to the host vas-
culature, thereby allowing dissemination and metastasis. An-
giogenesis is a tightly regulated process in which the relative
balance between proangiogenic factors and antiangiogenic fac-
tors determines whether new vessels are formed. Tumors in-
duce angiogenesis by disrupting this balance, often by upregu-
lating secretion of proangiogenic factors such as vascular
endothelial growth factor (VEGF) (8).
Virus-induced upregulation of angiogenesis factors in virally
mediated malignancies may play a significant role in tumor
progression. In the case of Kaposi’s sarcoma-associated herpes
virus, a close relative of EBV, multiple viral lytic proteins are
capable of inducing upregulation of VEGF (3, 6, 66). The
capacity of VEGF to induce angiogenesis is thought to con-
tribute to the development of Kaposi’s sarcoma (6), a highly
vascularized lesion, while the ability of VEGF to increase vas-
cular permeability may play a role in the pathogenesis of
Kaposi’s sarcoma-associated herpes virus-associated primary
effusion lymphoma (4, 5). Angiogenesis is also thought to be
critically important for the growth of the EBV-associated ma-
lignancies nasopharyngeal carcinoma (NPC) and Burkitt’s lym-
phoma (BL), as angiogenesis inhibitors are able to inhibit
tumor growth in mouse models of either malignancy (48, 50,
71). The viral latent protein LMP1, which is expressed in some
cases of NPC, may play a role by inducing expression of an-
giogenic factors such as VEGF, IL-8, and IL-6 in latently
infected tumor cells (15, 16, 43, 72). The contribution of EBV
lytic proteins to the regulation of tumor angiogenesis is largely
unknown.
In this paper we have examined whether lytic-defective
Z-KO LCLs are impaired in mediating angiogenesis in com-
parison to WT LCLs. Somewhat surprisingly, especially con-
sidering that only a few percent of WT LCLs have the lytic
form of viral infection, the supernatant of Z-KO LCLs from
two separate donors had significantly lower angiogenic activity
than the supernatant from WT LCLs. Furthermore, BZLF1
expression in trans restored angiogenic activity in the Z-KO
LCL supernatants. In comparison to WT LCLs, Z-KO and
R-KO LCLs secreted much lower amounts of the angiogenic
factor VEGF in vitro, and reintroduction of BZLF1 expression
in the Z-KO LCLs resulted in increased secretion of VEGF.
The difference in VEGF secretion in the lytic-defective versus
WT LCLs was not due to differences in transcription of VEGF,
since the WT and Z-KO LCLs expressed similar levels of
VEGF mRNA. Instead, one or more lytic EBV proteins pre-
sumably increase translation and/or secretion of VEGF. These
results suggest that in early-passage LCLs, angiogenic factors
are primarily derived from a small number of lytically infected
cells. The decreased secretion of angiogenesis factors in early-
passage lytic-defective LCLs, coupled with their known defect
in forming tumors in vivo, suggests that lytic induction of an-
giogenesis factors such as VEGF may play a significant role in
growth of some EBV-associated tumors.
MATERIALS AND METHODS
EBV wild-type, Z-KO, and R-KO viruses and cell lines. 293 cells infected with
the R-KO virus, Z-KO virus, and WT virus have been described previously (17).
In the R-KO virus, nucleotides 103638 to 105083 (strain B95.8 coordinates,
accession number V01555) within the BRLF1 gene were removed via insertion
of a tetracycline resistance cassette. In the Z-KO virus, nucleotides 102389 to
103388 (B95.8 coordinates) within the BZLF1 gene were removed via insertion
of a kanamycin resistance cassette. The R-KO, Z-KO, and WT viruses also
encode enhanced green fluorescent protein and a hygromycin B resistance gene
(both cloned into the B95.8 deletion of EBV where the second copy of oriLyt
normally resides). LCLs containing the WT, Z-KO, and R-KO viruses were
generated as described previously (25), using the supernatant of BZLF1- or
BRLF1-transfected 293 cells infected with Z-KO or R-KO virus, respectively, as
a source of virus and peripheral blood leukocytes derived from several different
anonymous donors (obtained from the American Red Cross). LCLs were main-
tained in RPMI medium supplemented with 10% fetal bovine serum and anti-
biotics. Z-KO and R-KO LCLs were verified to be BZLF1 and BRLF1 via
PCR with BZLF1- and BRLF1-specific primers.
Generation of Z-KO LCLs expressing BZLF1. pREP9-Zp-Z (which contains
the BZLF1 gene driven by its own promoter) was generated by cloning the 1.8-kb
BamHI Z EBV fragment (B95.8 genome) into the BamHI site of a modified
pREP9 vector (Invitrogen) in which the Rous sarcoma virus promoter had been
removed and a blasticidin resistance cassette was inserted. The pREP9 plasmid
contains the EBV oriP element and hence can be stably maintained as an
episome in EBNA-1-expressing LCLs. Stable Z-KO LCL lines containing either
the vector control (Z-KO-vector LCLs) or the pREP9-ZpZ expression vector
were generated using a nucleoporator (Amaxa) as previously described (26).
Matrigel in vitro HDMEC tube formation assay. Human dermal microvascu-
lar endothelial cells (HDMECs) were maintained in EGM-2 medium supple-
mented with 5% fetal bovine serum. Matrigel (125 l; growth factor reduced),
after being thawed on ice, was plated in eight-well chamber slides. These slides
were then incubated at 37°C for 30 min to allow the Matrigel to polymerize.
HDMECs (400 l; 4  104 cells/ml in EBM-2 medium without serum) were
added to each well and treated with 40 l of culture supernatant from LCLs
(1  106 cells cultured in 1 ml of serum-free medium for 24 h). VEGF (50 ng/ml)
was used as positive control, and medium alone was used as a negative control.
The chamber slides were then incubated for 16 to 18 h at 37°C in a 5% CO2
humidified atmosphere. At the end of incubation, the culture medium was very
carefully aspirated off the Matrigel surface, and the cells were fixed with meth-
anol and stained with Diff-Quick solution II. Each chamber was photographed
using an inverted microscope with a digital camera (Leica DMIRB, Germany)
and total tube area in each chamber was quantified using Metamorph software
(Universal Imaging Corporation, Downingtown, PA) and expressed as an angio-
genic score. P values were calculated using an Excel t test.
In vivo angiogenesis studies. LCL tumors generated in SCID mice injected
subcutaneously with 5  106 WT or Z-KO LCLs from the same donor (26) were
harvested once they reached 4 mm in diameter, fixed overnight in 10% neutral
buffered formalin, and embedded in paraffin. Hematoxylin- and eosin-stained
sections were examined under high power, and the number of vessels per five
high-powered fields was counted and averaged. For identification of human-
derived CD31 cells, tumor sections were deparaffinized and rehydrated. Fol-
lowing epitope retrieval, slides were stained using a human specific CD31 anti-
body (clone JC/70A; Ventana) on a BenchMark instrument (Ventana Medical
Systems, Inc).
Immunoblotting. Supernatants of LCLs growing for 2 days in serum-free
medium were concentrated 50-fold using ultrafiltration with Centricon col-
umns (Millipore, Billerica, MA). Equal amounts (micrograms) of concentrated
supernatants were subjected to sodium dodecyl sulfate-polyacrylamide gel elec-
trophoresis and immunoblotted using standard procedures with the following
primary antibodies: polyclonal rabbit anti-VEGF-A (1:500; Santa Cruz Biotech-
nology) and polyclonal rabbit anti-basic fibroblast growth factor (bFGF) (1:500;
Santa Cruz Biotechnology). Protein extracts from the cellular pellets collected at
the same time as the supernatants were also immunoblotted as described above
using the anti-VEGF-A antibody.
Reverse-transcription PCR (RT-PCR) analysis. LCLs were grown in serum-
free medium for 24 h, and total RNA was harvested using a QIAGEN RNeasy
Kit according to the manufacturer’s instructions. One microgram of RNA was
reverse transcribed using a Promega Reverse Transcription system according to
the manufacturer’s instructions. PCR was then performed using primers specific
for VEGF (7) and B2-microglobulin (41) using different dilutions of cDNA.
RESULTS
Z-KO LCL supernatants are less angiogenic than WT LCL
supernatants in vitro. To determine whether lytic infection con-
tributes to tumor angiogenesis, we utilized early-passage Z-KO
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LCLs, which we recently discovered have a tumorigenesis defect
in SCID mice (26). Z-KO LCLs are infected with a recombi-
nant EBV in which the BZLF1 immediate-early gene has been
deleted via insertional mutagenesis (17). The Z-KO virus can-
not replicate lytically unless BZLF1 is supplied in trans (17)
and, hence, represents a lytic-defective virus. Supernatants
from early-passage Z-KO or WT LCLs growing in vitro (de-
rived from the same donor) were tested for their ability to
induce endothelial tube formation in a Matrigel in vitro angio-
genesis assay (Fig. 1). WT LCL supernatants, as well as the
known angiogenic factor VEGF, were able to induce signifi-
cant endothelial tube formation. In sharp contrast, Z-KO LCL
supernatants induced minimal tube formation. Quantification
of tube formation revealed that WT LCL supernatants con-
tained approximately threefold more angiogenic activity than
Z-KO LCL supernatants (Fig. 1, right panel) (P  0.0001).
Given that the donor origin of LCLs can influence their
behavior both in vitro and in vivo (14, 30, 47), we next deter-
mined if Z-KO LCLs derived from a second donor were also
defective in their capacity to secrete angiogenesis factors in
comparison to the corresponding WT LCLs. Z-KO LCLs from
the second donor also secreted lower levels of angiogenesis
factors in comparison to the corresponding WT LCLs (Fig. 1),
indicating that the angiogenesis defect of Z-KO LCLs is not
donor specific. The decreased angiogenic activity of Z-KO
supernatants surprisingly suggests that the majority of secreted
angiogenesis factors in early-passage LCLs is derived from the
rare, lytically infected cells.
Restoring expression of BZLF1 in trans increases the angio-
genic capacity of Z-KO LCLs. Previous studies have demon-
strated that Z-KO LCLs have a similar viral latency profile to
WT LCLs (17, 26). To further verify that the difference be-
tween WT and Z-KO LCLs with regard to angiogenesis was
solely due to a lack of lytic gene expression, we created Z-KO
LCLs stably carrying either an oriP-replicated episomal control
vector (Z-KO-vector LCLs) or the same vector containing the
BZLF1 gene driven by the endogenous BZLF1 promoter
(Z-KO-ZpZ LCLs). Z-KO-ZpZ LCLs behaved similarly to
WT LCLs in their capacity to be induced into the lytic cycle in
vitro (data not shown); furthermore, tumors formed in SCID
FIG. 1. Z-KO LCL supernatants are less angiogenic than WT LCL supernatants in vitro. Supernatants from WT LCLs (WT) or Z-KO LCLs
(Z-KO) growing in vitro were tested for their ability to induce tube or vessel formation of HDMECs in vitro. VEGF, HDMECs treated with the
known angiogenic factor VEGF; () control, HDMECs treated with medium alone. Photomicrographs of a representative area of endothelial tube
formation within a chamber for each sample from donor 1 and donor 2 are shown. Quantification of the total tube area per chamber formed by
HDMECs treated with medium alone (control), medium from WT LCLs, or medium from Z-KO LCLs expressed as an angiogenic score (y axis)
is shown for each donor. Data represent the means of three independent experiments, each done in triplicate. Error bars indicate standard errors
of the mean. The results of LCLs derived from two different donors are shown.
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mice by Z-KO-ZpZ LCLs expressed viral lytic proteins in a few
percent of cells at a comparable level to WT LCL tumors (26).
As depicted in Fig. 2a, the supernatants from Z-KO-ZpZ
LCLs possessed approximately twofold higher angiogenic ac-
tivity than the Z-KO-vector supernatants, and this difference
was statistically significant (P  0.0001) (Fig. 2b). The in-
creased angiogenic capacity of Z-KO-ZpZ supernatants indi-
cates that restoration of BZLF1 expression increases secretion
of angiogenic factors.
Examination of angiogenesis in vivo. In order to determine
whether the in vitro angiogenesis defect in the Z-KO LCLs
could also be demonstrated in vivo, we analyzed tumors arising
in SCID mice following injection with either Z-KO or WT
LCLs. The degree of angiogenesis was not significantly differ-
ent between WT and Z-KO LCL tumors as determined by
vessel counts of hematoxylin- and eosin-stained tumor sec-
tions. The lack of an in vivo angiogenesis difference may simply
reflect the possibility that the tumors were harvested at a point
where an angiogenesis difference was minimized or no longer
apparent (see Discussion).
A recent report suggests that the vasculature within human
posttransplant lymphoproliferative disease (PTLD) is, unex-
pectedly, partially derived from lymphoma cells (61). The LCL
tumor vasculature in SCID mice can be stained with an anti-
body specific to the mouse form of CD31 (a marker routinely
used for detection of endothelial cells), and therefore at least
a portion of the vasculature in this animal model for PTLD is
derived from murine endothelial cells (69). To determine if the
vasculature within LCL tumors in SCID mice is also partially
derived from the LCLs themselves, we stained the tumors
using an antibody specific for the human form of CD31
(Fig. 3). Notably, some tumor vessels (Fig. 3a, arrow) as well as
individual LCLs (Fig. 3b, arrow) were strongly positive for
human CD31. While CD31 can be detected in lymphomas and
in some normal B-cell subsets (59), the human origin of the
tumor vasculature suggests that LCLs may directly contribute
to the formation of tumor vessels in SCID mice. However, we
did not detect a consistent difference in the degree of human
CD31 staining in either LCLs or the tumor vasculature be-
tween WT- and Z-KO LCL-derived tumors, suggesting that
lytic infection is not required for the ability of LCLs to become
endothelial cells.
Lytic-defective LCLs secrete less VEGF than WT LCLs in
vitro. Of the many positive regulators of angiogenesis, VEGF
represents the most potent angiogenic factor characterized to
date (18). To determine if the angiogenesis defect of Z-KO
LCLs was a consequence of decreased VEGF secretion, we
performed Western blot analysis of supernatants harvested
from serum-starved WT and Z-KO LCLs growing in vitro. As
depicted in Fig. 4a, Z-KO LCLs secreted markedly lower levels
of VEGF than WT LCLs, suggesting that lytically infected cells
are the major source of VEGF secretion. To verify that the
defect in VEGF secretion was due to a defect in lytic infection,
we also examined the supernatants from LCLs derived with the
lytic-defective R-KO virus. Similar to the Z-KO LCLs, R-KO
LCLs are also impaired for tumorigenesis in vivo while exhib-
iting a similar latency profile to WT LCLs (26). In comparison
to WT LCLs, R-KO LCLs (from the same donor) also exhib-
ited decreased secretion of VEGF (Fig. 4a). The decreased
secretion of VEGF in the lytic-defective LCLs did not reflect a
nonspecific defect in transcription, translation, or secretion, as
equivalent amounts of another well-known angiogenic factor,
bFGF, were secreted into the supernatants of WT, Z-KO, and
R-KO LCLs (Fig. 4a). Finally, to further demonstrate that a
defect in lytic gene expression was responsible for decreased
VEGF secretion, we examined supernatants from Z-KO LCLs
stably expressing BZLF1 in trans (under the control of its
natural promoter) (26). As demonstrated in Fig. 4b, Z-KO
LCLs carrying the BZLF1 expression vector (Z-KO-ZpZ) se-
creted higher levels of VEGF than the corresponding Z-KO
LCLs carrying the control vector (Z-KO-vector), again sug-
gesting that lytic infection contributes to the release of VEGF.
FIG. 2. Restoring the expression of BZLF1 in trans increases the
angiogenic capacity of Z-KO LCLs. (a) Supernatants from Z-KO
LCLs carrying a control vector (Z-KO-vector) or carrying a BZLF1
expression vector driven by the authentic BZLF1 promoter (Z-KO-
ZpZ) were tested for their ability to induce tube and vessel formation
of HDMECs in vitro. VEGF, HDMECs treated with the known an-
giogenic factor VEGF; () control, HDMECs treated with medium
alone. Photomicrographs of a representative area of endothelial tube
formation within a chamber for each sample are shown. (b) Quantifi-
cation of the total tube area per chamber formed by HDMECs treated
with medium alone (control), medium from Z-KO LCLs carrying a
control vector (Z-KO-vector), or medium from Z-KO LCLs carrying a
BZLF1 expression vector (Z-KO-ZpZ), expressed as an angiogenic
score (y axis). Data represent the means of three independent exper-
iments, each done in quadruplicate. Error bars indicate standard
errors of the mean.
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Lytic infection does not regulate VEGF at the level of tran-
scription. VEGF expression is intricately regulated through
both transcriptional and posttranscriptional mechanisms (46).
For example, in response to certain stimuli, the cell may upregu-
late transcription of VEGF, increase stability of the VEGF
mRNA, or enhance translational initiation of VEGF transcripts.
To determine if the increased secretion of VEGF observed in
WT LCLs is due to an upregulation of VEGF transcription, we
analyzed VEGF transcript levels using semiquantitative RT-
PCR. WT, Z-KO, and R-KO LCLs all expressed similar levels
of the various VEGF transcripts (Fig. 5a), suggesting that in-
creased secretion of VEGF in WT LCLs was not due to en-
hanced VEGF transcription. Furthermore, although reintro-
duction of BZLF1 expression in the Z-KO LCLs resulted in
increased secretion of VEGF, no increase in the level of
VEGF transcripts was observed in Z-KO LCLs carrying a
BZLF1 expression vector (Fig. 5b), again suggesting that lytic
infection enhances VEGF expression/secretion via a posttran-
scriptional mechanism.
Lytic-defective and WT LCLs have similar amounts of in-
tracellular VEGF protein. Immunoblot analysis was performed
on cellular extracts to determine if WT LCLs also have a
FIG. 3. Examination of angiogenesis in vivo. Z-KO LCL tumors were stained using an antibody specific for human CD31. Examples of tumor
vessels (a) and individual LCLs (b) staining positive for human CD31 are indicated by arrows. Similar results were obtained in WT LCL tumors
(data not shown).
FIG. 4. Lytic-defective LCLs secrete less VEGF than WT LCLs in vitro. (a) Supernatants from WT LCLs (WT), Z-KO LCLs (Z-KO), or R-KO
LCLs (R-KO) growing in vitro were concentrated and immunoblotted using either VEGF-A- or bFGF-specific antibodies. Arrows indicate
different forms of VEGF generated by alternative splicing. (b) Supernatants from Z-KO LCLs carrying a BZLF1 expression vector (Z-KO-ZpZ)
and Z-KO LCLs carrying the control vector (Z-KO-vector) were concentrated and immunoblotted using a VEGF-A specific antibody.
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higher level of intracellular VEGF protein than the lytic-de-
fective LCLs. As shown in Fig. 6a the amount of intracellular
VEGF protein was similar in the WT LCLs and the Z-KO and
R-KO LCLs. Furthermore, restoration of BZLF1 expression in
the Z-KO LCLs did not increase the amount of intracellular
VEGF (Fig. 6b). Since the total level (intracellular plus extracel-
lular) of VEGF is clearly greater in the WT versus lytic-defective
cells, while the amount of intracellular VEGF is similar, these
results suggest that lytic infection not only increases the total
amount of VEGF but also enhances its secretion.
DISCUSSION
EBV is strongly associated with several malignancies of both
B-cell and epithelial origin, and the presence of the virus is
believed to contribute to the growth of tumors in vivo (52).
Although the majority of cells within an EBV-associated ma-
lignancy are latently infected, small subsets of lytically infected
cells are frequently detected in several different malignancies
(11, 40, 42, 70). A role for lytic infection in malignancy was
recently demonstrated by our finding that early-passage LCLs
infected with lytic-defective viruses (Z-KO and R-KO LCLs)
were impaired for growth in SCID mice (26). Furthermore,
Z-KO and R-KO LCLs secreted lower levels of important
paracrine B-cell growth factors in vitro, suggesting that lytic
infection may contribute to the formation of EBV-associated
lymphomas via release of paracrine factors (26).
In this paper we demonstrate that lytic infection in early-
passage LCLs also induces angiogenesis, suggesting another
potential mechanism by which lytic infection may contribute to
malignancy. Supernatants from WT LCLs were more angio-
genic than supernatants from Z-KO LCLs, and this effect was
not dependent on the donor origin of the LCLs. Introduc-
tion of a BZLF1 expression vector into Z-KO LCLs, which
restores the capacity of Z-KO LCLs to enter lytic cycle (26),
enhanced the angiogenic activity of Z-KO LCL supernatants,
confirming that lytic infection in LCLs contributes to release of
FIG. 5. Lytic infection does not regulate VEGF at the level of transcription. A comparison of VEGF (a) or B2-microglobulin (B2-micro) (b)
transcription using RT-PCR in WT, Z-KO, and R-KO LCLs growing in vitro is shown. VEGF transcripts are alternatively spliced, leading to
multiple RT-PCR products. Different dilutions of starting cDNA amounts are shown to ensure linearity. A comparison of VEGF (c) or
B2-microglobulin (B2-micro) (d) transcription using RT-PCR in Z-KO LCLs carrying a control vector (Z-KO-vector) or a BZLF1 expression
vector (Z-KO-ZpZ) is shown. Different dilutions of starting cDNA amounts are shown to ensure linearity.
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angiogenesis factors. As growth of LCL tumors in SCID mice
is characterized by abundant angiogenesis (69) and angiogen-
esis inhibitors prevent growth of lymphoma cells in mice (48),
the impaired capacity of Z-KO LCLs to secrete angiogenesis
factors may contribute to their impaired growth in SCID mice.
Despite the readily apparent in vitro angiogenesis defect of
the Z-KO LCLs, we were not able to detect a striking differ-
ence in angiogenesis of WT or Z-KO LCLs tumors in vivo.
However, it should be noted that tumors were harvested once
they had reached a certain size, and since the Z-KO LCLs grow
at a significantly slower rate than WT LCLs in mice (26), the
Z-KO LCL tumors were harvested at a later time point than
the corresponding WT LCL tumors. Hence, by the time the
Z-KO LCL tumors reach harvest size (4 mm in diameter),
they might have already overcome an initial angiogenesis de-
fect (e.g., via genetic or epigenetic changes) that hinders
growth during the early stages of tumorigenesis. Indeed, as
angiogenesis is required after a cell is located 100 m from
an existing vessel (8), it seems likely that Z-KO LCL tumors
would have likely overcome any angiogenesis defect in order to
reach a size of 4 mm. Surprisingly, both Z-KO and WT LCL
tumors exhibited human CD31 staining of the tumor vascula-
ture, suggesting that at least a portion of the tumor vasculature
is derived from human LCLs as opposed to mouse endothelial
cells. A recent report indicates that the vascular cells within
different human B-cell lymphomas share the same specific
cytogenetic aberrations as the lymphoma cells, suggesting that
the tumor vasculature can be directly derived from the lym-
phoma cells themselves (61). Interestingly, as lymphoma cells
are known to express various degrees of CD31 (59) and hyp-
oxia can regulate differentiation of malignant cells (23, 29), the
possibility exists that LCLs could switch to an endothelial cell
phenotype in vivo under conditions where angiogenesis is
needed.
VEGF represents the most potent angiogenic factor charac-
terized to date and is frequently expressed by human B-cell
lymphoma cells in vitro and in vivo (19, 20, 24, 64). Both Z-KO
and R-KO LCLs secreted substantially lower levels of VEGF
than WT LCLs in vitro, suggesting that lytic infection induces
VEGF secretion. Furthermore, introduction of a BZLF1 ex-
pression vector into Z-KO LCLs enhanced secretion of VEGF.
As angiogenesis is a key requirement for lymphoma growth,
the impaired growth of Z-KO LCL tumors may be partly a
consequence of decreased angiogenesis due to insufficient
VEGF secretion. Decreased secretion of VEGF may also di-
rectly inhibit the growth of Z-KO LCLs in vivo, as VEGF can
function as an autocrine growth factor for lymphoma cells (65).
It should also be noted that VEGF stimulation of tumor stro-
mal cells may result in secretion of IL-6 (12), a potent B-cell
growth factor that enhances LCL growth in vivo (13, 62).
In addition to its potential effects during malignancy, lytic-
induced VEGF secretion may also influence viral pathogenesis
during normal infection. VEGF can functionally inhibit den-
dritic cell maturation (21), and thus induction of VEGF secre-
tion may assist the virus in lessening the host response during
lytic infection. VEGF also possesses antiapoptotic effects
(20, 22, 32, 35, 36, 44, 45, 65) and may prolong survival of the
host cell during lytic infection. Finally, secretion of VEGF can
recruit monocytes (10), a cell type capable of being infected
with EBV that has been proposed to serve as a vehicle for viral
dissemination (55, 56).
The regulation of VEGF is complex and involves both tran-
scriptional and posttranscriptional mechanisms (46). WT,
Z-KO, and R-KO LCLs expressed similar levels of VEGF
transcripts, suggesting that the decreased VEGF secretion in
lytic-defective LCLs is due to a difference in posttranscrip-
tional regulation. Translation of VEGF mRNA is regulated in
a cap-dependent manner by eIF-4E (34), an initiation factor
that is activated by stress kinase signaling (51, 67, 68). Inter-
estingly, both the BZLF1 and BRLF1 gene products activate
stress kinases (1), suggesting a possible mechanism for en-
hanced VEGF translation during the lytic viral cycle. VEGF
translation is also regulated in a cap-independent manner via
two internal ribosome entry site elements present in the 5
untranslated region of VEGF transcripts (2, 27, 60). Similar to
eIF-4E-mediated translation, internal ribosome entry site-me-
diated translation of some genes can also be positively regu-
lated by stress kinases (57), suggesting yet another mechanism
for lytic infection to increase VEGF translation. Our results
also suggest the possibility that lytic EBV infection enhances
the secretion of VEGF, as the level of extracellular VEGF was
clearly increased to a greater degree than the amount of in-
tracellular VEGF in lytically infected LCLs.
It is also possible that angiogenesis factors in addition to
VEGF contribute to the increased angiogenicity of the WT
LCL supernatants. Although VEGF is the most potent and
well-characterized angiogenesis factor to date, many other
positive regulators of angiogenesis are known, and the possi-
FIG. 6. Lytic-defective LCLs have a similar amount of intracellular
VEGF as WT LCLs in vitro. (a) Cellular extracts from WT LCLs
(WT), Z-KO LCLs (Z-KO), or R-KO LCLs (R-KO) growing in vitro
were immunoblotted using the VEGF-A-specific antibodies. (b) Cel-
lular extracts from Z-KO LCLs carrying a BZLF1 expression vector
(Z-KO-ZpZ) and Z-KO LCLs carrying the control vector (Z-KO-
vector) were immunoblotted using a VEGF-A-specific antibody.
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bility exists that lytic infection induces additional positive reg-
ulators of angiogenesis. It should also be noted that EBV has
the capacity to infect and replicate within endothelial cells in
vitro (31); furthermore, binding of the EBV virion to endothe-
lial cells induces secretion of IL-6 (31), another positive regu-
lator of angiogenesis. Hence, it is possible that lytic infection
also contributes to angiogenesis by direct interaction with or
infection of endothelial cells by EBV virions.
The angiogenesis studies presented in this paper were all
performed using LCLs. LCLs represent a suitable model for
EBV-associated PTLD, as injection of LCLs into SCID mice
results in lymphomas similar to PTLD in regard to viral gene
expression and histology (52, 54). Whether or not lytic infec-
tion contributes to angiogenesis in other types or models of
EBV malignancy is currently unknown. Latent infection has
been proposed to contribute to NPC angiogenesis via LMP1-
mediated secretion of the angiogenesis factors VEGF, IL-8,
and matrix metalloproteinases (MMPs) (38, 43, 72). Since up
to 65% of NPC biopsies exhibit no evidence of LMP1 protein
expression (52), lytic infection may be important for the induc-
tion of angiogenesis in the absence of LMP1. Indeed, BZLF1
can induce the angiogenesis factors MMP-1/MMP-9 in NPC
cells (38, 73) as well as transforming growth factor 	(9) in
other epithelial cell lines. BL, another EBV-associated B-cell
malignancy, frequently exhibits small subsets of lytically in-
fected cells (70) and is dependent on angiogenesis for success-
ful tumor growth in mouse models (48, 49). As BL does not
express LMP1, lytic infection may be important for angiogen-
esis and successful tumor growth in this context.
In conclusion, we demonstrate an unexpected and novel
contribution of lytic EBV infection in angiogenesis. In the
future it will be important to determine which lytic EBV pro-
tein(s) contributes to VEGF induction and the precise mech-
anism for this posttranscriptional effect. Our demonstration
that lytic infection in LCLs contributes to VEGF release has
important implications not only for angiogenesis in EBV-asso-
ciated tumors but also for understanding viral pathogenesis
during normal infection.
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